ArticleMedicine2026
Gut microbiota, immune cell traits, and major adverse cardiac events: A joint analysis of global burden of disease study and Mendelian randomization.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
As one of the primary composite endpoints in cardiovascular clinical research, major adverse cardiac events (MACE) are associated with poor clinical outcomes in patients with cardiovascular diseases. Gut microbiota and immune cells are increasingly recognized to be associated with MACE. However, the precise mechanisms remain unclear. We retrospectively analyzed the global burden of ischemic heart disease (IHD) and ischemic stroke (IS), 2 major contributors to the overall burden of MACE, by extracting data from the Global Burden of Disease database, and two-sample Mendelian randomization (MR) using the FinnGen R9 I9_CHD dataset as the outcome to investigate the genetically predicted associations between gut microbiota, immune cell traits, and major coronary heart disease events. In 2021, global IHD prevalence reached 254.3 million cases, a 1.4% increase from 1990, whereas IS prevalence declined by 39.6% over the same period. Results of Mendelian randomization analysis provided evidence supporting genetically predicted associations between 21 gut microbiota, 31 immune cells, and major coronary heart disease event. Sensitivity tests confirmed our findings. Additionally, mediation analysis suggested that the association between gut microbiota and major coronary heart disease event may be partly mediated through immune cell traits. Our study provides both an updated epidemiological profile of IHD/IS and genetic evidence linking gut microbiota and immune cell traits to coronary events, with immune cells potentially acting as mediators. These findings provide a foundation for future mechanistic studies and may facilitate the identification of candidate therapeutic targets, although further experimental validation is required.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.